Carisma Therapeutics (CARM)

Executive Summary

Carisma Therapeutics (NASDAQ: CARM) is a clinical-stage biopharmaceutical company pioneering engineered macrophage (CAR-M) and monocyte (CAR-Mono) cell therapies for solid tumors. Its lead candidate, CT-0508, an anti-HER2 CAR-M, is being evaluated in a Phase 1 trial in combination with pembrolizumab for HER2-positive solid tumors. Additionally, CT-0525, an anti-HER2 CAR-Monocyte, has also entered Phase 1. The company's platform aims to overcome the limitations of T-cell therapies in solid tumors by leveraging macrophages' natural tumor infiltration and antigen-presenting capabilities. With a market capitalization of approximately $17 million, Carisma is at an early stage with no approved products. Upcoming data readouts from these Phase 1 trials represent pivotal milestones that could validate the platform's potential and drive near-term value. The company also faces significant financial and clinical risks typical of early-stage biotech.

Upcoming Catalysts (preview)

• Q2 2026Interim efficacy and safety data from CT-0508 + pembrolizumab Phase 1 trial (NCT04660929)60% success
• Q2 2026Topline data from CT-0525 Phase 1 monotherapy trial (NCT06254807)60% success
• 2H 2026Potential partnership or licensing deal to advance platform30% success